Kristi Rosa

1 week ago | targetedonc.com | Kristi Rosa

The immunotherapy combination of pembrolizumab (Keytruda) plus concurrent chemoradiation therapy (cCRT) continued to deliver durable responses and a manageable safety profile among patients with unresectable, locally advanced, stage III non–small cell lung cancer (NSCLC), according to data from the final analysis of the phase 2 KEYNOTE-799 trial (NCT03631784) presented during the 2025 European Lung Cancer Congress.1 In cohort A (n=112), which comprised patients with squamous or nonsquamous...

1 week ago | onclive.com | Kristi Rosa

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of subcutaneous formulation of daratumumab (daratumumab and hyaluronidase-fihj; Darzalex Faspro) for use as a single agent in adult patients with smoldering multiple myeloma that is at high risk of developing multiple myeloma.1 The recommendation is supported by findings from the phase 3 AQUILA study (NCT03301220), which showed that at a median follow-up of 65.2 months (range,...

1 week ago | targetedonc.com | Kristi Rosa

For patients with EGFR-mutated non–small cell lung cancer (NSCLC) who have progressed on frontline osimertinib (Tagrisso), the combination of osimertinib plus datopotamab deruxtecan (Dato-DXd; Datroway) given at 4 or 6 mg/kg demonstrated encouraging efficacy with acceptable safety, according to an analysis of module 10 of the phase 2 ORCHARD study (NCT03944772).1 The data, which were shared during the 2025 European Lung Cancer Congress (ELCC), indicated that the objective response rate (ORR)...

1 week ago | targetedonc.com | Kristi Rosa

The primary end point of the phase 3b ASC4START trial (NCT05456191) has been met as asciminib (Scemblix) led to better tolerability vs that observed with nilotinib (Tasigna) in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) based on treatment discontinuation due to adverse effects (TTDAE).1 Findings, which were shared at the 2025 ASCO Annual Meeting,2 and now at the 2025 European Hematology Association Congress,1 revealed a statistically significant...

1 week ago | targetedonc.com | Kristi Rosa

The primary end point of the phase 3b ASC4START trial (NCT05456191) has been met as asciminib (Scemblix) led to better tolerability vs that observed with nilotinib (Tasigna) in patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase (CML-CP) based on treatment discontinuation due to adverse effects (TTDAE).1 Findings, which were shared at the 2025 ASCO Annual Meeting,2 and now at the 2025 European Hematology Association Congress,1 revealed a statistically significant...